A 14 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in an environmental exposition unit (Vienna Challenge Chamber) in subjects with seasonal allergic rhinitis (SAR).
Phase of Trial: Phase II
Latest Information Update: 26 May 2011
At a glance
- Drugs GSK 256066 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- 26 May 2011 New trial record